Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 9/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 9/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5352313 | 0.80 | MAPT (0.42) | MAPTMAPK1HTTCHRNB2CHRNA4 | |
| SCHEMBL27923808 | 0.78 | CHKA (0.46) | MAPTNPSR1 | |
| SCHEMBL28380433 | 0.77 | LMNA (0.31) | MAPTNPSR1 | |
| SCHEMBL29626231 | 0.73 | CYP2A6 (0.41) | MAPTMAPK1HTTCHRNB2CHRNA4 | |
| SCHEMBL27977591 | 0.73 | CYP2A6 (0.41) | MAPTMAPK1HTTCHRNB2CHRNA4 | |
| SCHEMBL29137307 | 0.71 | CYP2A6 (0.40) | MAPTMAPK1HTTCHRNB2CHRNA4 | |
| Benzene SCHEMBL28093687 | 0.71 | MAPT (0.41) | MAPTMAPK1HTTCHRNB2CHRNA4 | |
| SCHEMBL28194545 | 0.71 | CHRNB2 (0.42) | MAPTMAPK1HTTCHRNB2CHRNA4 | |
| Pyrazole SCHEMBL28821521 | 0.71 | MAPT (0.38) | MAPTMAPK1HTTNPSR1 | |
| SCHEMBL983193 | 0.70 | CYP2A6 (0.42) | MAPTMAPK1HTTCHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020045618-A1 | Heteroaryl diazacycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2002-04-18 | — | — | US | claimed |
| CN-113999201-B | Synthesis and preparation method of nicotine | 成昌梅 | 2023-11-03 | — | — | CN | disclosed |
| CN-113999201-A | Synthetic preparation method of nicotine | 成昌梅 | 2022-02-01 | — | — | CN | disclosed |
| US-20180042909-A1 | Methods of Treating Cancers, Autoimmune Disorders, and Other Conditions Associated with Chronic Inflammation | MYMD PHARMACEUTICALS, INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180042909-A1 | Methods of Treating Cancers, Autoimmune Disorders, and Other Conditions Associated with Chronic Inflammation | MYMD PHARMACEUTICALS, INC. (US) | 2018-02-15 | — | — | US | disclosed |
| CN-106470976-A | The method of preparation 3 (3 chlorine 1H pyrazoles 1 base) pyridine | 美国陶氏益农公司 | 2017-03-01 | — | — | CN | disclosed |
| US-20020045618-A1 | Heteroaryl diazacycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045618-A1 | Heteroaryl diazacycloalkanes, their preparation and use | CHRNA5, CHRNA7, CHRNA3 | MAPT 1195/4885MAPK1 1592/4885HTT 885/4885 |
| US-20180042909-A1 | Methods of Treating Cancers, Autoimmune Disorders, and Other Conditions Associated with Chronic Inflammation | ROS1, NOX4, MPO | MAPT 1874/4885MAPK1 811/4885HTT 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.